After the approval of abraxane (albumin-paclitaxel nanoparticle), clinical trials using abraxane have been conducted and these have showed substantial clinical activity among advanced pancreatic cancer patients [48], manageable safety profile with antitumor responses in metastatic triple-negative breast cancer patients [49], and antitumor activity in women with ERBB2/HER2-negative breast cancer [50]. This evidence concerns the gene ERBB2 and pancreatic neoplasm.